# Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

> **NCT07499674** · PHASE3 · RECRUITING · sponsor: **Vergent Bioscience, Inc.** · enrollment: 132 (estimated)

## Conditions studied

- Lung Cancer
- Lung Metastases

## Interventions

- **DRUG:** Abenacianine
- **OTHER:** Near Infrared (NIR) Imaging

## Key facts

- **NCT ID:** NCT07499674
- **Lead sponsor:** Vergent Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07499674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07499674, "Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07499674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*